Clearside Biomedical is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. The company’s proprietary SCS Microinjector® targeting the suprachoroidal space (SCS®) offers unique access to the macula, retina and choroid where sight-threatening disease often occurs.
Using the company’s suprachoroidal injection technology that can be used in conjunction with proprietary formulations of existing drugs, novel therapies, as well as future therapeurtic innovastions, the company believes that it has created a broad therapeutic platform for developing product candidates to treat serious eye diseases.
Eyenovia, Inc. (NASDAQ: EYEN) is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP) therapeutics. Eyenovia’s pipeline is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression and mydriasis.
Founded based on the research of Professors Noriko Koizumi and Naoki Okumura at Doshisha University in Kyoto, Japan, ActualEyes is a Japan-based clinical stage biotech company committed to the research and development of both cell therapy and pharmacological treatments for corneal endothelial dysfunction, including Fuchs endothelial corneal dystrophy (FECD) and bullous keratopathy.
Olympic Ophthalmics, Inc. is a medical technology company pioneering patient-focused treatments for ophthalmic diseases using neuromodulation. The company is based in Issaquah, Washington, and primarily backed by BioStar Capital, a physician-led, strategic value-add investment firm focused on accelerating value creation for transformational medical device and connected health technologies.